|
| Effects of bevacizumab on quality of life and serum VEGF levels in patients with pulmonary adenocarcinoma with brain metastasis and refractory cerebral edema VLOG |
| Hits 1304 Download times 1247 Received:March 20, 2020 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1673-9043.2020.04.13 |
| Key Words
lung adenocarcinoma;VEGF;refractory cerebral edema;quality of life;bevacizumab |
| Author Name | Affiliation | E-mail | | WANG Yao | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | | | DU Lehui | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | | | LIU Fang | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | | | YANG Wei | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | | | MA Na | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | | | QU Baolin | Chinese PLA General Hosptial, Radiotherapy Department, Beijing 100853, China | qubl6212@sina.com |
|
| Abstract
|
| [Objective] To study the effects of bevacizumab on quality of life and serum VEGF levels in patients with pulmonary adenocarcinoma with brain metastasis and refractory cerebral edema (belonging to lung rock with fontanelle filling or craniectomy).[Methods] From January 2016 to December 2019,sixty patients with lung adenocarcinoma with brain metastasis and refractory brain edema admitted to our hospital were included in the study. They were divided into research group and traditional group by random number table. The traditional group received traditional treatments such as hormone and mannitol,while the research group received bevacizumab. The changes of edema index (EI),quality of life and serum VEGF level,and the occurrence of adverse reactions were compared between the two groups before and after treatment.[Results] After treatment,EI in the research group and the traditional group was lower than that before treatment,and EI in the research group was lower than that in the traditional group (P<0.05). After treatment,the scores of life quality of the research group and the traditional group were higher than before treatment,and the scores of the research group were higher than that of the traditional group (P<0.05). After treatment,the serum VEGF level of the research group and the traditional group was lower than that before treatment,and the research group was lower than that of the traditional group (P<0.05). There was no significant difference in the incidence of blood in sputum,blood in the stool and proteinuria between the research group and the traditional group (P>0.05). The proportion of headache,dizziness and vomiting in the study group was higher than that in the traditional group (P<0.05).[Conclusion] Bevacizumab can effectively improve the quality of life and serum VEGF level of patients with lung adenocarcinoma with brain metastasis and refractory brain edema without increasing the risk of adverse reactions. |
|
|
|
|
|
